{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:36:07Z","timestamp":1761568567604,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clgc.2014.10.001","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T02:41:39Z","timestamp":1414118499000},"page":"199-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients"],"prefix":"10.1016","volume":"13","author":[{"given":"Paulo","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1vio","family":"Hering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio","family":"Imperio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2014.10.001_bib1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.10.001_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000099336","article-title":"Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects","volume":"78","author":"Bottke","year":"2007","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2014.10.001_bib3","first-page":"1423","article-title":"Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications","volume":"178","author":"Krupski","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.10.001_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A\u00a0randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2014.10.001_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1442-2042.2006.01721.x","article-title":"Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study","volume":"14","author":"Rodrigues","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2014.10.001_bib6","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.10.001_bib7","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boisier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2014.10.001_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.pcan.4500752","article-title":"Use of bisphosphonates can dramatically improve pain in advanced hormone refractory prostate cancer patients","volume":"7","author":"Rodrigues","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2014.10.001_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1590\/S1677-55382003000300006","article-title":"Clodronate for the treatment of bone metastases in hormone refractory prostate cancer","volume":"29","author":"Hering","year":"2003","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.clgc.2014.10.001_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationship between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2014.10.001_bib11","first-page":"42s","article-title":"Inhibitory effects of zoledronic acid on prostate epithelial and bone marrow progenitor cells","volume":"30","author":"Montague","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2014.10.001_bib12","first-page":"246","article-title":"Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells","volume":"170","author":"Oades","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.10.001_bib13","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2014.10.001_bib14","unstructured":"Clinicaltrials.gov [Web site]. Effect of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00219271. Accessed in May, 2012."},{"key":"10.1016\/j.clgc.2014.10.001_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00007-1","article-title":"Costs of prostate cancer, metastatic to the bone, in The Netherlands","volume":"43","author":"Groot","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2014.10.001_bib16","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphonates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.10.001_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.10.001_bib18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.10.001_bib19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tavetyano","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.10.001_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2014.10.001_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.10.001_bib22","first-page":"177","article-title":"Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: a word of caution","volume":"10","author":"Zanglis","year":"2007","journal-title":"Hell J Nucl Med"},{"key":"10.1016\/j.clgc.2014.10.001_bib23","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.10.001_bib24","first-page":"100","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.10.001_bib25","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","article-title":"Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?","volume":"17","author":"Van den Wyngaert","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.10.001_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2006.11.023","article-title":"Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder","volume":"40","author":"Dannemann","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2014.10.001_bib27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","article-title":"Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis","volume":"33","author":"Amin","year":"1992","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clgc.2014.10.001_bib28","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jbmr.5650111015","article-title":"Bisphosphonates induce apoptosis in mouse macrophage-like cells in\u00a0vitro by a nitric oxideindependent mechanism","volume":"11","author":"Rogers","year":"1996","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clgc.2014.10.001_bib29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0026-895X(25)09541-0","article-title":"Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages","volume":"50","author":"Selander","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clgc.2014.10.001_bib30","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [published erratum appears in: J Clin Oncol 2004; 22:1351]","volume":"21","author":"Hillner","year":"2003","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314002316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314002316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:24:41Z","timestamp":1761564281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767314002316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1558767314002316"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2014.10.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2014.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}